Search research articles
Contact Us
Filters
Showing results (51-60 of 77) with videos related to
Page
of 8
Sort By:
World Journal of Urology
|
September 15, 2022
Testicular germ cell tumours' clinical stage I: comparison of surveillance with adjuvant treatment strategies regarding recurrence rates and overall survival-a systematic review
Christian G Ruf, Stefanie Schmidt, Sabine Kliesch, et al.
Journal of Cancer Research and Clinical Oncology
|
April 4, 2014
First salvage treatment in patients with advanced germ cell cancer after cisplatin-based chemotherapy: analysis of a registry of the German Testicular Cancer Study Group (GTCSG)
Lars Arne Berger, Carsten Bokemeyer, Anja Lorch, et al.
European Urology Oncology
|
August 13, 2023
Combining PARP Inhibitors and Androgen Receptor Signalling Inhibitors in Metastatic Prostate Cancer: A Quantitative Synthesis and Meta-analysis
Carlo Messina, Emilio Francesco Giunta, Alessio Signori, et al.
Molecular Oncology
|
January 25, 2023
Preclinical patient-derived modeling of castration-resistant prostate cancer facilitates individualized assessment of homologous recombination repair deficient disease
Mohamed E Elsesy, Su Jung Oh-Hohenhorst, Christoph Oing, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 5, 2018
Questioning the Value of Fluorodeoxyglucose Positron Emission Tomography for Residual Lesions After Chemotherapy for Metastatic Seminoma: Results of an International Global Germ Cell Cancer Group Registry
Richard Cathomas, Dirk Klingbiel, Brandon Bernard, et al.
Journal of Experimental & Clinical Cancer Research : CR
|
August 27, 2021
The component of the m<sup>6</sup>A writer complex VIRMA is implicated in aggressive tumor phenotype, DNA damage response and cisplatin resistance in germ cell tumors
Vera Miranda-Gonçalves, João Lobo, Catarina Guimarães-Teixeira, et al.
Cancers
|
October 14, 2020
Efficacy of HDAC Inhibitors Belinostat and Panobinostat against Cisplatin-Sensitive and Cisplatin-Resistant Testicular Germ Cell Tumors
João Lobo, Catarina Guimarães-Teixeira, Daniela Barros-Silva, et al.
Oncology Research and Treatment
|
December 6, 2022
Career and Professional Development for Young Oncologists
Maximilian J Mair, Claudia Cardone, Liz Connolly, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 20, 2022
Chromosome 3p25.3 Gain Is Associated With Cisplatin Resistance and Is an Independent Predictor of Poor Outcome in Male Malignant Germ Cell Tumors
Dennis M Timmerman, Thomas F Eleveld, Sruthi Sriram, et al.
Cancers
|
September 4, 2020
Second-Generation Antiandrogen Therapy Radiosensitizes Prostate Cancer Regardless of Castration State through Inhibition of DNA Double Strand Break Repair
Mohamed E Elsesy, Su Jung Oh-Hohenhorst, Anastassia Löser, et al.
Page
of 8
Search research articles
Search
Showing results (51-60 of 77) with videos related to
Sort By:
Page
of 8
World Journal of Urology
|
September 15, 2022
Testicular germ cell tumours' clinical stage I: comparison of surveillance with adjuvant treatment strategies regarding recurrence rates and overall survival-a systematic review
Christian G Ruf, Stefanie Schmidt, Sabine Kliesch, et al.
Journal of Cancer Research and Clinical Oncology
|
April 4, 2014
First salvage treatment in patients with advanced germ cell cancer after cisplatin-based chemotherapy: analysis of a registry of the German Testicular Cancer Study Group (GTCSG)
Lars Arne Berger, Carsten Bokemeyer, Anja Lorch, et al.
European Urology Oncology
|
August 13, 2023
Combining PARP Inhibitors and Androgen Receptor Signalling Inhibitors in Metastatic Prostate Cancer: A Quantitative Synthesis and Meta-analysis
Carlo Messina, Emilio Francesco Giunta, Alessio Signori, et al.
Molecular Oncology
|
January 25, 2023
Preclinical patient-derived modeling of castration-resistant prostate cancer facilitates individualized assessment of homologous recombination repair deficient disease
Mohamed E Elsesy, Su Jung Oh-Hohenhorst, Christoph Oing, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 5, 2018
Questioning the Value of Fluorodeoxyglucose Positron Emission Tomography for Residual Lesions After Chemotherapy for Metastatic Seminoma: Results of an International Global Germ Cell Cancer Group Registry
Richard Cathomas, Dirk Klingbiel, Brandon Bernard, et al.
Journal of Experimental & Clinical Cancer Research : CR
|
August 27, 2021
The component of the m<sup>6</sup>A writer complex VIRMA is implicated in aggressive tumor phenotype, DNA damage response and cisplatin resistance in germ cell tumors
Vera Miranda-Gonçalves, João Lobo, Catarina Guimarães-Teixeira, et al.
Cancers
|
October 14, 2020
Efficacy of HDAC Inhibitors Belinostat and Panobinostat against Cisplatin-Sensitive and Cisplatin-Resistant Testicular Germ Cell Tumors
João Lobo, Catarina Guimarães-Teixeira, Daniela Barros-Silva, et al.
Oncology Research and Treatment
|
December 6, 2022
Career and Professional Development for Young Oncologists
Maximilian J Mair, Claudia Cardone, Liz Connolly, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 20, 2022
Chromosome 3p25.3 Gain Is Associated With Cisplatin Resistance and Is an Independent Predictor of Poor Outcome in Male Malignant Germ Cell Tumors
Dennis M Timmerman, Thomas F Eleveld, Sruthi Sriram, et al.
Cancers
|
September 4, 2020
Second-Generation Antiandrogen Therapy Radiosensitizes Prostate Cancer Regardless of Castration State through Inhibition of DNA Double Strand Break Repair
Mohamed E Elsesy, Su Jung Oh-Hohenhorst, Anastassia Löser, et al.
Page
of 8